During the past decade, Ulsan University Hospital conducted 145 clinical trials. In the 10-year time frame, 145 clinical trials started and 43 clinical trials were completed, i.e. on average, 29.7% percent of trials that started reached the finish line to date. In the past 5 years, 63 clinical trials started and 26 clinical trials were completed. i.e. 41.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ulsan University Hospital" #1 sponsor was "Seung-Jung Park" with 36 trials, followed by "Ulsan University Hospital" with 22 trials sponsored, "Hoffmann-La Roche" with 18 trials sponsored, "Pfizer" with 12 trials sponsored and "Asan Medical Center" with 12 trials sponsored. Other sponsors include 139 different institutions and companies that sponsored additional 84 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ulsan University Hospital" #1 collaborator was "CardioVascular Research Foundation, Korea" with 40 trials as a collaborator, "Ulsan University Hospital" with 15 trials as a collaborator, "Seoul National University Hospital" with 6 trials as a collaborator, "Asan Medical Center" with 5 trials as a collaborator and "Inje University" with 5 trials as a collaborator. Other collaborators include 187 different institutions and companies that were collaborators in the rest 140 trials.

According to Clinical.Site data, the most researched conditions in "Ulsan University Hospital" are "Coronary Artery Disease" (48 trials), "Breast Cancer" (9 trials), "Cardiovascular Diseases" (6 trials), "Coronary Disease" (6 trials) and "Multiple Myeloma" (6 trials). Many other conditions were trialed in "Ulsan University Hospital" in a lesser frequency.

Most popular intervention types in "Ulsan University Hospital" are "Drug" (133 trials), "Device" (43 trials), "Procedure" (16 trials), "Biological" (15 trials) and "Other" (14 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Atezolizumab" (9 trials), "Cypher" (4 trials), "Paclitaxel" (4 trials) and "Percutaneous coronary intervention" (4 trials). Other intervention names were less common.

The vast majority of trials in "Ulsan University Hospital" are 233 trials for "All" genders, 7 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Ulsan University Hospital". 1 are not yet recruiting, 38 are recruiting, 38 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 106 completed trials in Ulsan University Hospital, undefined suspended trials, and 19 terminated clinical trials to date.

Out of the total trials that were conducted in Ulsan University Hospital, 8 "Phase 1" clinical trials were conducted, 35 "Phase 2" clinical trials and 66 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 41 trials, and there were also 26 trials that are defined as “Not Applicable".